Arcticzymes Technologies ASA
OSE:AZT

Watchlist Manager
Arcticzymes Technologies ASA Logo
Arcticzymes Technologies ASA
OSE:AZT
Watchlist
Price: 19.1 NOK
Market Cap: 975.4m NOK
Section:
 

Relative Value

The Relative Value of one AZT stock under the Base Case scenario is 23.51 NOK. Compared to the current market price of 19.1 NOK, Arcticzymes Technologies ASA is Undervalued by 19%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AZT Relative Value
Base Case
23.51 NOK
Undervaluation 19%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

10
P/S
P/S
Price to Sales
10
vs History
79
vs Industry
47
Median 3Y
12.7
Median 5Y
17
Industry
7.9
Forward
8.7
More Details
347.9
P/E
P/E
Price to Earnings
347.9
vs History
11
vs Industry
1
Median 3Y
110.7
Median 5Y
87.2
Industry
24
Forward
140.1
More Details
92.5
P/OCF
P/OCF
Price to OCF
92.5
vs History
23
vs Industry
0
Median 3Y
71.2
Median 5Y
65.6
Industry
21.6
More Details
538.8
P/FCFE
P/FCFE
Price to FCFE
538.8
vs History
11
vs Industry
0
Median 3Y
128.3
Median 5Y
80.4
Industry
23.7
More Details
3
P/B
P/B
Price to Book Value
3
vs History
80
vs Industry
33
Median 3Y
4.4
Median 5Y
6.9
Industry
3.4
More Details
7.5
EV/S
EV/S
Enterprise Value to Sales
7.5
vs History
79
vs Industry
43
Median 3Y
10.7
Median 5Y
15
Industry
8.3
Forward
6.5
More Details
7.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.9
vs History
79
vs Industry
48
Median 3Y
11.2
Median 5Y
15.6
Industry
10.3
More Details
1 725.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
1 725.4
vs History
6
vs Industry
1
Median 3Y
82.6
Median 5Y
73.4
Industry
6.7
Forward
90.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
1
Median 3Y
57.7
Median 5Y
68.8
Industry
7.2
Forward
-726
More Details
69.5
EV/OCF
EV/OCF
Enterprise Value to OCF
69.5
vs History
33
vs Industry
0
Median 3Y
62.8
Median 5Y
61.8
Industry
8.2
More Details
133.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
133.4
vs History
25
vs Industry
1
Median 3Y
94.2
Median 5Y
73.3
Industry
6.7
More Details
8.1
EV/IC
EV/IC
Enterprise Value to IC
8.1
vs History
76
vs Industry
32
Median 3Y
12.1
Median 5Y
22.7
Industry
5.7
More Details

Multiples Across Competitors

AZT Competitors Multiples
Arcticzymes Technologies ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Arcticzymes Technologies ASA
OSE:AZT
975.5m NOK 10 347.9 1 725.4 -95.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 924 975 -161 240.4 -195 797.2 -193 563
US
Abbvie Inc
NYSE:ABBV
398B USD 6.7 169.5 16.4 23.3
US
Amgen Inc
NASDAQ:AMGN
169.7B USD 4.7 24.2 17.6 17.6
US
Gilead Sciences Inc
NASDAQ:GILD
150.7B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.9B USD 9.6 30.7 22.5 23.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 076.6 -529.9 -577 -561.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.5B USD 5.4 16.7 15.9 18
AU
CSL Ltd
ASX:CSL
86.6B AUD 3.7 19.3 13 16.2
NL
argenx SE
XBRU:ARGX
46.4B EUR 15.1 35.5 61.2 62.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.3B USD 16.6 1 223.6 160.8 195
P/E Multiple
Earnings Growth PEG
NO
Arcticzymes Technologies ASA
OSE:AZT
Average P/E: 209.5
347.9
64%
5.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 240.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
169.5
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.2
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.7
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
9%
1.9
AU
CSL Ltd
ASX:CSL
19.3
11%
1.8
NL
argenx SE
XBRU:ARGX
35.5
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 223.6
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
Arcticzymes Technologies ASA
OSE:AZT
Average EV/EBITDA: 227.2
1 725.4
111%
15.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 797.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.6
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -577 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
11%
1.4
AU
CSL Ltd
ASX:CSL
13
8%
1.6
NL
argenx SE
XBRU:ARGX
61.2
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
160.8
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
Arcticzymes Technologies ASA
OSE:AZT
Average EV/EBIT: 46.1
Negative Multiple: -95.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 563 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.3
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.6
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
13%
1.4
AU
CSL Ltd
ASX:CSL
16.2
11%
1.5
NL
argenx SE
XBRU:ARGX
62.9
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
195
N/A N/A

See Also

Summary
AZT intrinsic value, competitors valuation, and company profile.
DCF Valuation
AZT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AZT stock valuation using valuation multiples.
Wall Street Estimates
AZT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AZT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 302,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.